Evidence map›Paper›PMID 30344945›Full record

ArticleOncotarget2018

Overexpression of KDM5B/JARID1B is associated with poor prognosis in hepatocellular carcinoma.

Yoshinobu Shigekawa, Shinya Hayami, Masaki Ueno, Atsushi Miyamoto, Norihiko Suzaki, Manabu Kawai, Seiko Hirono, Ken-Ichi Okada, Ryuji Hamamoto, Hiroki Yamaue

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yoshinobu ShigekawaSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Shinya HayamiSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Masaki UenoSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Atsushi MiyamotoSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Norihiko SuzakiSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Manabu KawaiSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Seiko HironoSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Ken-Ichi OkadaSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Ryuji HamamotoDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan.
Hiroki YamaueSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan.
Wakayama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsHepatocellular carcinoma (HCC) has high potential for recurrence, even in curative operative cases. Although several molecular-targeting drugs have been applied to recurrent HCC, their effectiveness has been limited. This study therefore aims to develop novel cancer drugs through protein methylation.

methodsWe investigated the role of KDM5B/JARID1B, a member of JmjC histone demethylase, in HCC. Expression profiles of KDM5B were examined by immunohistochemical analysis in 105 HCC clinical tissue samples. To examine functional effects of KDM5B using HCC cell lines, we performed loss-of-function analysis treated with KDM5B-specific small interfering RNAs (siKDM5B).

resultsAll HCC cases were divided into KDM5B-positive expression group (n=54) and negative expression group (n=51). In five-year overall survival, KDM5B-positive group had poorer prognosis than KDM5B-negative (61% vs 77%,

conclusionsOverexpression of KDM5B results in poor prognosis in HCC that especially derived from HBV/HCV. KDM5B appears to be an ideal target for the development of anti-cancer drugs.

Indexed as

epigeneticshepatocellular carcinoma (HCC)histone demethylaseKDM5B/JARID1B

Identifiers

PMID30344945
PMCPMC6188148
OpenAlexW2892647453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.